The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack Jr; William Jagust; John C Morris; Ronald C Petersen; Jennifer Salazar; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski; Alzheimer's Disease Neuroimaging Initiative

doi:10.1016/j.jalz.2016.10.006

The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

Alzheimers Dement. 2017 May;13(5):561-571. doi: 10.1016/j.jalz.2016.10.006. Epub 2016 Dec 5.

Authors

Michael W Weiner¹, Dallas P Veitch², Paul S Aisen³, Laurel A Beckett⁴, Nigel J Cairns⁵, Robert C Green⁶, Danielle Harvey⁴, Clifford R Jack Jr⁷, William Jagust⁸, John C Morris³, Ronald C Petersen⁹, Jennifer Salazar³, Andrew J Saykin¹⁰, Leslie M Shaw¹¹, Arthur W Toga¹², John Q Trojanowski¹³; Alzheimer's Disease Neuroimaging Initiative

Affiliations

¹ Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA; Department of Radiology, University of California, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, CA, USA; Department of Psychiatry, University of California, San Francisco, CA, USA; Department of Neurology, University of California, San Francisco, CA, USA. Electronic address: michael.weiner@ucsf.edu.
² Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA.
³ Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA.
⁴ Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, USA.
⁵ Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, MO, USA; Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
⁶ Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
⁷ Department of Radiology, Mayo Clinic, Rochester, MN, USA.
⁸ Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA.
⁹ Department of Neurology, Mayo Clinic, Rochester, MN, USA.
¹⁰ Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
¹¹ Tailored Therapeutics, Eli Lilly and Company, Indianapolis, IN, USA.
¹² Laboratory of Neuroimaging, Institute of Neuroimaging and Informatics, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.
¹³ Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Alzheimer's Disease Core Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Udall Parkinson's Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Abstract

Introduction: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study.

Methods: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition.

Results: Multimodal analyses will provide insight into AD pathophysiology and disease progression.

Discussion: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.

Keywords: Alzheimer's disease; Amyloid phenotyping; Brain Health Registry; Centiloid method; Clinical trial biomarkers; Functional connectivity; Tau imaging.

Publication types

Review

MeSH terms

Alzheimer Disease / diagnostic imaging*
Alzheimer Disease / physiopathology*
Biomarkers / cerebrospinal fluid
Brain / diagnostic imaging
Clinical Trials as Topic*
Disease Progression
Humans
Magnetic Resonance Imaging
Neuroimaging*
Positron-Emission Tomography
Radionuclide Imaging

Substances

Biomarkers

Abstract

Publication types

MeSH terms

Substances

Grants and funding